Skip to main content

Neurology vs Immunology — Deal Terms Comparison

Neurology Median Upfront
$343M
Total: $3.0B
Immunology Median Upfront
$480M
Total: $2.5B
Neurology Royalties
12.4%-19.8%
Tiered to 23.8%
Immunology Royalties
13.2%-22.1%
Tiered to 26.1%

Market Analysis

Neurology and Immunology represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 neurology deals carry a median total deal value of $3.0B with $343M upfront, compared to $2.5B total value and $480M upfront for immunology. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do neurology and immunology deal terms compare?
Neurology Phase 2 deals average $3.0B total value ($343M upfront), while Immunology deals average $2.5B ($480M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating